Company intelligence / Profile preview

Dharmacon

Lafayette, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Dharmacon is a leading provider of synthetic oligonucleotides, RNAi, and CRISPR reagents for genetic research and functional genomics, now operating as part of Horizon Discovery (itself acquired by Revvity)[1][2][3][5]. Its technologies are used by academic and biotech/pharma researchers globally for gene modulation, gene editing, and high-throughput screening, but it does not have a drug or clinical pipeline; rather, it supplies enabling research tools utilized across all therapeutic disease areas and target types.

Modalities: Small interfering RNASynthetic oligonucleotideCRISPR-based therapyGuide RNA therapyShort hairpin RNA therapy
Industry: Non-Drug Biotech

Partnerships

Broad Institute of MIT and Harvard (CRISPR licensing)Various academic and industry relationships in gene editing and modulation fields

Beyond the preview

Go deeper on Dharmacon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dharmacon.

Explore the full profile